Clinical Trial: Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07841899) titled 'Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)' on Sept. 07.

Brief Summary: This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Diabetic Macular Edema (DME)

Intervention: DRUG: OLN324

OLN324 by intravitreal injection at protocol-specified dosing intervals

DRUG: Aflibercept

Aflibercept by intravitreal injection at protocol specified dosing intervals

Recruitment Status: NOT_YET_RECRUITING

Sp...